Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Seroquel XR for MDD

The FDA has approved Seroquel XR as an adjunctive treatment to antidepressants in adults with Major Depressive Disorder

AstraZeneca (AZ) today announced that the US Food and Drug Administration (FDA) has approved once-daily Seroquel XR (quetiapine fumarate) extended release tablets as an adjunctive treatment to antidepressants in adults with Major Depressive Disorder (MDD).

Manufactured by AZ, Seroquel XR is the only medication in its class approved by the FDA to treat both MDD as an adjunctive therapy, and acute depressive episodes associated with bipolar disorder as monotherapy. 

Traditionally MDD has been treated with antidepressants, with selective serotonin reuptake inhibitors (SSRIs) among the most commonly prescribed class. In many cases, however, patients fail to respond adequately to treatment. The approval for Seroquel  XR provides physicians with a new adjunctive treatment option for patients with MDD who have an inadequate response to their current antidepressant. 

In addition to this approval of Seroquel XR for the adjunctive indication in MDD, AZ has received a Complete Response Letter (CRL) from the FDA asking for additional information for the Supplemental New Drug Application (SNDA) for Seroquel XR as acute monotherapy and maintenance monotherapy for the treatment of MDD in adult patients. 

AZ is evaluating the contents of the CRL and will provide a response to the FDA in due course. The CRL does not change the current recommendations for the treatment of patients taking Seroquel XR for approved indications in schizophrenia and bipolar disorder. 

The FDA also requires that AZ implement a Risk Evaluation and Mitigation Strategy (REMS) for Seroquel XR, consisting of a medication guide and periodic assessments that will include a survey of patients' understanding of the potential risks of the drug. The REMS applies to all approved indications.

7th December 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics